Aoife Regan gives an update from the summer, discussing about the Phase I: Where Science Becomes Medicine conference, changes in the Programme Office, and her thoughts for the future.
The new Lead of the Birmingham ECMC talks to us about his career to date, the biggest challenges facing clinical research, and the exciting, unpredictable future for immunotherapy.
Gareth Veal discusses his team’s new therapeutic drug monitoring service, aiming to assist in the treatment particularly “hard-to-treat” childhood cancer patients.
Aoife Regan has recently returned from maternity leave back to her position as Head of the ECMC Programme Office. Aoife reflects on what’s changed in the network while she’s been away, what she’s planning to focus on and the challenges to come.
The new Lead of the Manchester ECMC talks to us about her career to date, balancing NHS service and clinical research commitments, precision medicine ... and the Enigma code.
Congratulations on your recent appointment. Can you tell us a little bit about your background, and why you got into clinical research?
Congratulations and welcome! Which aspects of your new role are you most excited about?
As part of my role I will lead on the creation of the Experimental Cancer (EC) Trial finder. This database will allow clinical staff to find the most relevant trial for their patients within the ECMC network, based on specific search criteria, including patient molecular profile.
Can you tell us a little bit about your work, and why you got into clinical research?
My main driver for getting into clinical research was to serve patients. My current work is focused on the conduct of clinical trials pursuing proof of mechanism and proof of concept, as well as translational cancer research.
How did it feel to be awarded this prestigious honour?